Bradley Hamilton

All Publications

• Cell-line and Antibody Epitope-dependent Expression Models Inform Selection of AAV-GNE Epimerase/Kinase Transgenes to Treat GNE Myopathy Patil, R., Hamilton, B., Day, J. CELL PRESS. 2025

  View details for Web of Science ID 001521601100226

• Innate Immune Avoidance by Extracellular Vesicle Associated AAV (EV-AAV) Hamilton, B. A., de la Cruz, D., Patil, R., Cheng, M., Wright, J., Maguire, C. A. CELL PRESS. 2024: 727

  View details for Web of Science ID 001332783402482

• A Strategy to Select Minimally Immunogenic Candidate AAV Vectors to Treat GNE Myopathy Hamilton, B. A., Patil, R., Ruland, B., Day, J., Wright, J. CELL PRESS. 2024: 726-727

  View details for Web of Science ID 001332783402481

• A Biosynthetic Approach for CpG Methylation of AAV Expression Cassettes Huellen, F., Patil, R., Hamilton, B. A., Wright, J. CELL PRESS. 2023: 113-114

  View details for Web of Science ID 001045144200211

• A Human PBMC Assay of Type 1 Interferon Responses to Closely Related AAV Vectors Hamilton, B. A., Patil, R., Kim, S., Day, J. W., Wright, J. CELL PRESS. 2023: 76

  View details for Web of Science ID 001045144200141

• Methylation of CpG Dinucleotides in AAV Vector Plasmids Reduces TLR9 Immune Activation Patil, R., Hamilton, B., Perriman, R., Wright, J. CELL PRESS. 2022: 66-67

  View details for Web of Science ID 000794043700125

• ITRS FROM AAV SEROTYPES DIFFERENTIALLY STIMULATE INNATE IMMUNE SIGNALING THROUGH TLR9 Hamilton, B., Patil, R., Wright, F. ELSEVIER SCIENCE INC. 2022: S92

  View details for Web of Science ID 000890643400145

• Challenges Posed by Immune Responses to AAV Vectors: Addressing Root Causes. Frontiers in immunology Hamilton, B. A., Wright, J. F. 2021; 12: 675897

  Abstract

  Host immune responses that limit durable therapeutic gene expression and cause clinically significant inflammation remain a major barrier to broadly successful development of adeno-associated virus (AAV)-based human gene therapies. In this article, mechanisms of humoral and cellular immune responses to the viral vector are discussed. A perspective is provided that removal of pathogen-associated molecular patterns in AAV vector genomes to prevent the generation of innate immune danger signals following administration is a key strategy to overcome immunological barriers.

  View details for DOI 10.3389/fimmu.2021.675897

  View details for PubMedID 34084173